

Alimatravir (AMI) Licensing Timeline

Merck/MSD announced initial voluntary license agreements with seven generic manufacturers to produce its investigational monthly oral PrEP candidate, alimatravir, well ahead of efficacy trial results. This builds on years of advocacy to shorten the timeline between scientific breakthroughs and public health impact.

